|Bid||87.03 x 1800|
|Ask||89.75 x 1100|
|Day's Range||85.68 - 87.33|
|52 Week Range||78.95 - 116.49|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||14.06|
|Earnings Date||Feb 14, 2019|
|Forward Dividend & Yield||2.12 (2.49%)|
|1y Target Est||98.13|
Quest Diagnostics CEO Steve Rusckowski on where the opportunities for growth are for the laboratory-services company, the growth of the health-care sector and efforts to reduce health-care spending in America.
Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.
# Quest Diagnostics Inc ### NYSE:DGX View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for DGX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $12.02 billion over the last one-month into ETFs that hold DGX are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. DGX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SECAUCUS, N.J., Jan. 14, 2019 /PRNewswire/ -- Americans have multiple numbers at their fingertips, but some of the numbers that could be most important to their health are not among them. New research released today by Quest Diagnostics (DGX), the world's leading provider of diagnostic insights, shows that a majority of adults don't know vital health information for them or their family members, but nearly all would like to be able to access their health information online. Results from the "Know Your Numbers" survey show that more people remember their social media log-ins, current bank balances, Wi-Fi-passwords and even the security code on the back of their credit card than they do important personal health data, including their blood type and cholesterol and blood sugar levels.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-424-7881 for domestic callers or 203-369-0869 for international callers, no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on February 14, 2019 until midnight Eastern Time on February 28, 2019. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
SECAUCUS, N.J., Jan. 2, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 37th Annual J. P. Morgan Healthcare Conference in San Francisco. Stephen Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Let's talk about the popular Quest Diagnostics Incorporated (NYSE:DGX). The company's shares received a lot of attention from a substantial price movement on the NYSE over the last few months, Read More...
SECAUCUS, N.J. , Dec. 21, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed the sale of its India ...
SECAUCUS, N.J., Dec. 19, 2018 /PRNewswire/ -- Drug use by the U.S. workforce increased each year -- and by double-digits over two years -- between 2015 and 2017, in five of 16 major U.S. industry sectors analyzed, according to a first-ever analysis of industry-specific data from more than ten million urine drug test results performed by Quest Diagnostics (DGX), the world's leading provider of diagnostic information services. The data from the Quest Diagnostics Drug Testing Index™ industry analysis show that the Retail Trade (5.3%), Health Care and Social Assistance (4.7%), and Real Estate Rental and Leasing (4.6%) sectors had the highest overall positivity rates in 2017, while the Utilities (2.8%) and Finance and Insurance (2.6%) sectors had the lowest rates.
Amazon's (AMZN) growing healthcare initiatives are likely to aid its growth in the healthcare supply chain management market.
Of the ten analysts covering DaVita (DVA), five have given it “buy” or higher ratings, four have given it “holds,” and one has given it a “sell.”
In the third quarter, DaVita’s (DVA) patient care and other costs rose YoY (year-over-year) to $2.06 billion from $1.95 billion. Its gross margin expanded YoY to 27.52% from 25.41%. Expected trends
DaVita’s (DVA) two major business divisions are Kidney Care (DaVita Kidney Care) and DMG (DaVita Medical Group). The Kidney Care division includes its US dialysis and associated lab services, ancillary services, and strategic initiatives such as pharmacy services, disease management, vascular access services, and clinical research programs.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
Steve Rusckowski has been the CEO of Quest Diagnostics Incorporated (NYSE:DGX) since 2012. First, this article will compare CEO compensation with compensation at other large companies. Then we'll look at Read More...
SECAUCUS, N.J., Dec. 4, 2018 /PRNewswire/ -- Nearly 80 percent of hospital executives surveyed are not at all familiar, or only somewhat familiar, with the Protecting Access to Medicare Act (PAMA) and its impact on hospitals, according to a survey conducted by Modern Healthcare Custom Media on behalf of Quest Diagnostics (DGX), the world's leading provider of diagnostic information services. "The data presented here support what we've experienced in the health care marketplace," said Steve Rusckowski, Chairman, President and CEO of Quest Diagnostics. "Many C-suite executives of hospital health systems aren't aware of the impact of PAMA on the profitability of their outreach laboratories, especially when the PAMA cuts were first enacted.
Pilot Launched in April under Leadership of Humana, MultiPlan, Optum, Quest Diagnostics and UnitedHealthcare
Investing.com - The Dow snapped a three-day winning streak Thursday, pressured by selling moments before the close, even as minutes from the Fed's November meeting fueled expectations for a slower pace of rate hikes.